Biotest AG:Biotest successfully concludes 10% capital increase
Biotest AG / Capital Increase
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest successfully concludes 10% capital increase
Dreieich, 21 September 2007. Biotest AG, Dreieich has increased its share
capital by 10%. The 599,567 new ordinary shares and 466,666 new preference
shares were placed through an accelerated bookbuilding process and under
the exclusion of subscription rights among institutional shareholders. With
an issue price of EUR 32.70 per ordinary share and EUR 29.00 per preference
share gross issue proceeds for Biotest at a total of EUR 33.1 million.
This sum will be used to part fund the long-term bank loan provided by
Commerzbank AG for the acquisition of the plasma protein business of Nabi
Biopharmaceuticals Corp. Announced last week, the transaction is set to be
concluded by the end of 2007 following US merger control approval and the
approval of the Nabi Biopharmaceuticals shareholders.
The capital increase was significantly oversubscribed. The majority
shareholders of Biotest AG, the Schleussner family, participated in the
capital increase in accordance with its stake at the time of the
transaction. The Schleussner family therefore maintains its shareholding of
just over 50%. The remaining ordinary shares as well as the new preference
shares were placed with German and international institutional investors.
Particularly notable is the high allotment of both ordinary and preference
shares to UK investors.
Following the registration of the capital increase, the share capital of
Biotest AG totals around EUR 30.03 million. This sum is divided into
6,595,242 ordinary shares and 5,133,333 non-voting preference shares. The
remaining subscribed capital amounts to around EUR 0.69 million. Biotest
was supported in the transaction by the Frankfurt-based investment bank,
equinet.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
The information contained in this document may not be published or
distributed into Canada, Australia or Japan. Neither does it constitute any
offer to purchase securities in these countries.
The placement of shares and the distribution of this document in other
jurisdictions may be restricted by law and persons into whose possession
this document comes should inform themselves about and observe any such
restrictions. Any failure to comply with this restriction may constitute a
violation of the respective securities law.
This document does not constitute any offer to purchase securities in the
United States or other countries. This document is for distribution in the
UK only to (i) persons who have professional experience in matters relating
to investments falling within article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (The 'Order') or (ii)
high net worth entities falling within article 49(2)a to (d) of the order
(all such persons together being referred to as 'relevant persons'). All
securities to which reference is made in this document are directed only at
relevant persons and all requests, offers and agreements to obtain,
purchase or otherwise acquire these securities will only be considered if
made by relevant persons. Other persons should not act or rely on this
document or any of its contents.
This document does not constitute any offer to purchase securities in
Germany. Neither does it constitute a sales prospectus in accordance with
the German Securities Prospectus Act (WpPG), the Commission Regulation (EC)
Nr. 809/2004 of 29 April or other legislation applicable in Germany, which
regulate the issue, offer and sale of securities.
The information contained in this document may not be distributed into or
within the United States, Australia, Japan or Canada.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.
Biotest AG:
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-7840
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
21.09.2007 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich
Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
E-mail: mail@biotest.de
Internet: www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
